人工多能性幹細胞製造の世界市場2022年-2026年

【英語タイトル】Global Induced Pluripotent Stem Cells Production Market 2022-2026

Technavioが出版した調査資料(IRTNTR71329)・商品コード:IRTNTR71329
・発行会社(調査会社):Technavio
・発行日:2021年10月22日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:グローバル
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥325,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥390,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥520,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
テクナビオ社は、人工多能性幹細胞製造の世界市場規模が2021年~2025年まで年平均11.39%成長し、15.5億ドルに達すると予測しています。本市場調査レポートでは、世界の人工多能性幹細胞製造市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模、ファイブフォース分析、エンドユーザー別(病院、研究機関、バイオテクノロジー企業、その他)分析、顧客状況、地域別状況、企業状況、企業分析など、以下の構成でまとめております。
・エグゼクティブサマリー
・市場状況
・市場規模
・ファイブフォース分析
・人工多能性幹細胞製造の世界市場規模:エンドユーザー別(病院、研究機関、バイオテクノロジー企業、その他)
・顧客状況
・地域別状況
・企業状況
・企業分析
❖ レポートの概要 ❖

Global Induced Pluripotent Stem Cells Production Market 2022-2026
Technavio has been monitoring the induced pluripotent stem cells production market and it is poised to grow by $ 1.55 bn during 2022-2026, progressing at a CAGR of 11.39% during the forecast period. Our report on the induced pluripotent stem cells production market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by technological advancements in manufacturing and rising prevalence of several chronic disorders such as diabetes, heart disease, stroke and cancer. In addition, technological advancements in manufacturing is anticipated to boost the growth of the market as well.
The induced pluripotent stem cells production market analysis includes the end-user segment and geographic landscape.

Technavio’s induced pluripotent stem cells production market is segmented as below:

By End-user
• Hospitals
• Research institutes
• Biotechnology companies
• Others

By Geographical Landscape
• North America
• Europe
• Asia
• ROW

This study identifies the rising financial assistance by governmentsas one of the prime reasons driving the induced pluripotent stem cells production market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on induced pluripotent stem cells production market covers the following areas:
• Induced pluripotent stem cells production market sizing
• Induced pluripotent stem cells production market forecast
• Induced pluripotent stem cells production market industry analysis

Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading induced pluripotent stem cells production market vendors that include Applied StemCell Inc., Axol Biosciences Ltd., Evotec SE, Fate Therapeutics Inc., Hitachi Ltd., LIFE & BRAIN GmbH, Lonza Group Ltd., Merck KGaA, REPROCELL Inc., and Thermo Fisher Scientific Inc. Also, the induced pluripotent stem cells production market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors. For further information on this report, please visit – https://www.technavio.com/report/induced-pluripotent-stem-cells-production-market-industry-analysis

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research – both primary and secondary. Technavio’s market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

❖ レポートの目次 ❖

• Executive Summary
o Market overview
• Market Landscape
o Market ecosystem
o Value chain analysis
• Market Sizing
o Market definition
o Market segment analysis
o Market size 2021
o Market outlook: Forecast for 2021 – 2026
• Five Forces Analysis
o Bargaining power of buyers
o Bargaining power of suppliers
o Threat of new entrants
o Threat of substitutes
o Threat of rivalry
o Market condition
• Market Segmentation by End-user
o Market segments
o Comparison by End-user
o Hospitals – Market size and forecast 2021-2026
o Research institutes – Market size and forecast 2021-2026
o Biotechnology companies – Market size and forecast 2021-2026
o Others – Market size and forecast 2021-2026
o Market opportunity by End-user
• Customer landscape
• Geographic Landscape
o Geographic segmentation
o Geographic comparison
o North America – Market size and forecast 2021-2026
o Europe – Market size and forecast 2021-2026
o Asia – Market size and forecast 2021-2026
o ROW – Market size and forecast 2021-2026
o Key leading countries
o Market opportunity By Geographical Landscape
o Market drivers
o Market challenges
o Market trends
• Vendor Landscape
o Overview
o Landscape disruption
• Vendor Analysis
o Vendors covered
o Market positioning of vendors
o Applied StemCell Inc.
o Axol Biosciences Ltd.
o Evotec SE
o Fate Therapeutics Inc.
o Hitachi Ltd.
o LIFE & BRAIN GmbH
o Lonza Group Ltd.
o Merck KGaA
o REPROCELL Inc.
o Thermo Fisher Scientific Inc.
• Appendix
o Scope of the report
o Currency conversion rates for US$
o Research methodology
o List of abbreviations

Exhibits
• 1: Key Finding 1
• 2: Key Finding 2
• 3: Key Finding 3
• 4: Key Finding 5
• 5: Key Finding 6
• 6: Key Finding 7
• 7: Key Finding 8
• 8: Parent market
• 9: Market characteristics
• 10: Offerings of vendors included in the market definition
• 11: Market segments
• 12: Global – Market size and forecast 2021 – 2026 ($ million)
• 13: Global market: Year-over-year growth 2021 – 2026 (%)
• 14: Five forces analysis 2021 & 2026
• 15: Bargaining power of buyers
• 16: Bargaining power of suppliers
• 17: Threat of new entrants
• 18: Threat of substitutes
• 19: Threat of rivalry
• 20: Market condition – Five forces 2021
• 21: End-user – Market share 2021-2026 (%)
• 22: Comparison by End-user
• 23: Hospitals – Market size and forecast 2021-2026 ($ million)
• 24: Hospitals – Year-over-year growth 2021-2026 (%)
• 25: Research institutes – Market size and forecast 2021-2026 ($ million)
• 26: Research institutes – Year-over-year growth 2021-2026 (%)
• 27: Biotechnology companies – Market size and forecast 2021-2026 ($ million)
• 28: Biotechnology companies – Year-over-year growth 2021-2026 (%)
• 29: Others – Market size and forecast 2021-2026 ($ million)
• 30: Others – Year-over-year growth 2021-2026 (%)
• 31: Market opportunity by End-user
• 32: Customer landscape
• 33: Market share By Geographical Landscape 2021-2026 (%)
• 34: Geographic comparison
• 35: North America – Market size and forecast 2021-2026 ($ million)
• 36: North America – Year-over-year growth 2021-2026 (%)
• 37: Europe – Market size and forecast 2021-2026 ($ million)
• 38: Europe – Year-over-year growth 2021-2026 (%)
• 39: Asia – Market size and forecast 2021-2026 ($ million)
• 40: Asia – Year-over-year growth 2021-2026 (%)
• 41: ROW – Market size and forecast 2021-2026 ($ million)
• 42: ROW – Year-over-year growth 2021-2026 (%)
• 43: Key leading countries
• 44: Market opportunity By Geographical Landscape ($ million)
• 45: Impact of drivers and challenges
• 46: Vendor landscape
• 47: Landscape disruption
• 48: Industry risks
• 49: Vendors covered
• 50: Market positioning of vendors
• 51: Applied StemCell Inc. – Overview
• 52: Applied StemCell Inc. – Product and service
• 53: Applied StemCell Inc. – Key offerings
• 54: Applied StemCell Inc. – Key customers
• 55: Applied StemCell Inc. – Segment focus
• 56: Axol Biosciences Ltd. – Overview
• 57: Axol Biosciences Ltd. – Product and service
• 58: Axol Biosciences Ltd. – Key offerings
• 59: Axol Biosciences Ltd. – Key customers
• 60: Axol Biosciences Ltd. – Segment focus
• 61: Evotec SE – Overview
• 62: Evotec SE – Business segments
• 63: Evotec SE – Key offerings
• 64: Evotec SE – Key customers
• 65: Evotec SE – Segment focus
• 66: Fate Therapeutics Inc. – Overview
• 67: Fate Therapeutics Inc. – Product and service
• 68: Fate Therapeutics Inc. – Key offerings
• 69: Fate Therapeutics Inc. – Key customers
• 70: Fate Therapeutics Inc. – Segment focus
• 71: Hitachi Ltd. – Overview
• 72: Hitachi Ltd. – Business segments
• 73: Hitachi Ltd. – Key offerings
• 74: Hitachi Ltd. – Key customers
• 75: Hitachi Ltd. – Segment focus
• 76: LIFE & BRAIN GmbH – Overview
• 77: LIFE & BRAIN GmbH – Product and service
• 78: LIFE & BRAIN GmbH – Key offerings
• 79: LIFE & BRAIN GmbH – Key customers
• 80: LIFE & BRAIN GmbH – Segment focus
• 81: Lonza Group Ltd. – Overview
• 82: Lonza Group Ltd. – Business segments
• 83: Lonza Group Ltd. – Key offerings
• 84: Lonza Group Ltd. – Key customers
• 85: Lonza Group Ltd. – Segment focus
• 86: Merck KGaA – Overview
• 87: Merck KGaA – Business segments
• 88: Merck KGaA – Key offerings
• 89: Merck KGaA – Key customers
• 90: Merck KGaA – Segment focus
• 91: REPROCELL Inc. – Overview
• 92: REPROCELL Inc. – Product and service
• 93: REPROCELL Inc. – Key offerings
• 94: REPROCELL Inc. – Key customers
• 95: REPROCELL Inc. – Segment focus
• 96: Thermo Fisher Scientific Inc. – Overview
• 97: Thermo Fisher Scientific Inc. – Business segments
• 98: Thermo Fisher Scientific Inc. – Key offerings
• 99: Thermo Fisher Scientific Inc. – Key customers
• 100: Thermo Fisher Scientific Inc. – Segment focus
• 101: Currency conversion rates for US$
• 102: Research Methodology
• 103: Validation techniques employed for market sizing
• 104: Information sources
• 105: List of abbreviations



❖ 掲載企業 ❖

Applied StemCell Inc., Axol Biosciences Ltd., Evotec SE, Fate Therapeutics Inc., Hitachi Ltd., LIFE & BRAIN GmbH, Lonza Group Ltd., Merck KGaA, REPROCELL Inc., Thermo Fisher Scientific Inc.

★調査レポート[人工多能性幹細胞製造の世界市場2022年-2026年] (コード:IRTNTR71329)販売に関する免責事項を必ずご確認ください。
★調査レポート[人工多能性幹細胞製造の世界市場2022年-2026年]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆